目的 探討盤龍七片聯(lián)合依托考昔治療膝骨關(guān)節(jié)炎的臨床效果。方法 選取2019年6月—2020年12月天津市第一中心醫(yī)院收治的134例膝骨關(guān)節(jié)炎患者，隨機(jī)分成對照組（67例）和治療組（67例）。對照組口服依托考昔片，1片/次，1次/d。治療組在對照組基礎(chǔ)上口服盤龍七片，3片/次，3次/d。兩組連續(xù)治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者主要癥狀與體征改善情況，膝骨性關(guān)節(jié)炎生存質(zhì)量量表（QOL-KOA）評分，血清白細(xì)胞介素-1β（IL-1β）、基質(zhì)金屬蛋白酶-9（MMP-9）、血管內(nèi)皮生長因子（VEGF）、轉(zhuǎn)化生長因子β1（TGF-β1）、一氧化氮（NO）水平。結(jié)果 治療后，治療組總有效率為95.5%，明顯高于對照組的85.1%（P＜0.05）。治療后，兩組患者膝關(guān)節(jié)疼痛視覺模擬量表（VAS）評分和西安大略和麥克馬斯特大學(xué)骨關(guān)節(jié)炎指數(shù)（WOMAC）總分均顯著低于同組治療前（P＜0.05），晨僵時間顯著短于治療前（P＜0.05），且均以治療組的改善更顯著（P＜0.05）。治療后，兩組QOL-KOA中各項目評分及其總分均顯著降低（P＜0.05），且治療組的降低更顯著（P＜0.05）。治療后，兩組血清IL-1β、MMP-9、VEGF和NO含量均顯著低于同組治療前，血清TGF-β1水平均顯著高于本組治療前（P＜0.05），且治療組明顯好于對照組（P＜0.05）。結(jié)論 盤龍七片聯(lián)合依托考昔治療膝骨關(guān)節(jié)炎的整體療效滿意，能安全有效地緩解患者癥狀與體征，提高生活質(zhì)量。

Objective To investigate the clinical effect of Panlongqi Tablets combined with etoricoxib in treatment of knee osteoarthritis.Methods Patients (134 cases) with knee osteoarthritis in Tianjin First Central Hospital from June 2019 to December 2020 were randomly divided into control (67 cases) and treatment (67 cases) group. Patients in the control group were po administered with Etoricoxib Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Panlongqi Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the improvement of main symptoms and signs, QOL-KOA scores, the levels of serum IL-1β, MMP-9, VEGF, TGF-β1 and NO in two groups before and after treatment were compared.Results After treatment, the total effective rate of the treatment group was 95.5%, which was significantly higher than that of the control group (85.1%) (P < 0.05). After treatment, the VAS score and the total score of WOMAC in two groups were significantly lower than those before treatment, and the time of morning stiffness in the treatment group was significantly shorter than that before treatment (P < 0.05), and the improvement in the treatment group was more significant (P < 0.05). After treatment, the scores of each item and the total score of QOL-KOA in two groups were significantly decreased (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the levels of serum IL-1β, MMP-9, VEGF and NO in two groups were significantly lower than those before treatment, and the average level of serum TGF-β1 in two groups was significantly higher (P < 0.05), which in the treatment group were significantly better than the control group (P < 0.05).Conclusion The overall curative effect of Panlongqi Tablets combined with etoricoxib in treatment of knee osteoarthritis is satisfactory, which can safely and effectively alleviate the patients' symptoms and signs and improve the quality of life.

R977